Skip to main content

Table 1 Characteristics of pemafibrate interventions included in the present meta-analysis compared with placebo or fenofibrate interventions

From: Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis

No. References Year Region No. of patients Age (years) % women BMI (kg/m2) Diabetes (%) Hypertension (%) Statin (%) Study duration (weeks) TG (mmol/L)
1 Ishibashi et al. [11] 2016 Japan 224 48 2.9 26.8 11.4 25.7 0 12 3.4
2 Arai et al. [17] 2017 Japan 423 55 20 26.2 29.3 58.5 100 24 4.3
3 Arai et al. [12] 2018 Japan 526 49 12 26.9 16.3 34.9 0 12 346 (mg/dL)
4 Araki et al. [18] 2018 Japan 166 61 34 26 100 37 40.4 24 3.2
5 Ishibashi et al. [19] 2018 Japan 225 53 21 26.1 6.8 24.7 0 24 2.7
6 Matsuba et al. [20] 2018 Japan 27 46 0 25.8 0 18.2 0 12 3.4
7 Yamashita et al. [21] 2018 Japan 32 52 29 25 12.5 31.3 0 4 2.9
  1. Unless indicated otherwise, data are shown as mean values
  2. BMI body mass index, TG triglycerides